Structure Therapeutics Inc.
NASDAQGPCR enters the week with a sharp split between the data and the price action. The most important development is the publication of Phase 2b results for aleniglipron in Nature Medicine on June 5. The data showed up to 16.2% weight loss in the ACCESS obesity trial, and management confirmed the Phase 3 programme is on track to start in Q3 2026. That is a material de-risking…
Snapshot as of 6 Jun 2026
GPCR enters the week with a sharp split between the data and the price action. The most important development is the publication of Phase 2b results for aleniglipron in Nature Medicine on June 5. The data showed up to…
GPCR heads into its Q1 2026 earnings print with the options market sending its most bullish signal of the year — even as the stock has shed nearly a quarter of its value over the past month. The divergence is the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for GPCR — free to start on ORTEX.
Sign up for free →Open GPCR on ORTEX